Inositol phosphoglycan signaling pathway (IPG signaling pathway)

The Inositol phosphoglycan (IPG) signaling pathway is a secondary messenger system that mediates the intracellular actions of insulin and other growth factors. Upon hormone binding to its receptor, IPGs are released from glycosylphosphatidylinositol (GPI) anchors in the cell membrane via the action of phospholipases (Larner, 2002, Int J Exp Diabetes Res). These molecules are classified into two main types: IPG-A (containing myo-inositol and glucosamine) and IPG-P (containing D-chiro-inositol and galactosamine), each exerting distinct effects on metabolic enzymes like glycogen synthase and pyruvate dehydrogenase (Scioscia et al., 2014, J Reprod Immunol). Dysregulation of this pathway, particularly a deficiency in D-chiro-inositol-containing IPGs, is a hallmark of insulin resistance and is frequently observed in patients with Type 2 diabetes and Polycystic Ovary Syndrome (PCOS) (Nestler et al., 1999, NEJM). Pharmacological intervention typically focuses on the administration of inositol isomers to replenish the pool of precursors available for IPG synthesis, thereby improving insulin sensitivity and ovulatory function (Unfer et al., 2017, Endocr Connect). However, because this pathway involves a broad range of downstream effectors, achieving high therapeutic specificity remains a significant challenge in drug development.

Other names

IPG pathwayInositol glycan signalingGlycosyl-phosphatidylinositol-derived second messenger system

Inositol phosphoglycans act as second messengers that activate specific phosphatases (such as PP2C) and inhibit kinases (such as PKA), thereby modulating the activity of rate-limiting metabolic enzymes like glycogen synthase and pyruvate dehydrogenase to enhance insulin sensitivity (Larner, 2002, Int J Exp Diabetes Res).